Using air filtration to slow heart disease progression
Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History
This study is testing if using air filters in homes can help slow down heart disease in adults who have had heart problems before.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 112 (estimated) |
| Ages | 65 Years to 84 Years |
| Sex | All |
| Sponsor | University of Southern California Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05867381 on ClinicalTrials.gov |
What this trial studies
This double-blind, randomized, crossover trial investigates whether long-term indoor air filtration can slow the progression of atherothrombosis in adults with a history of ischemic heart disease. The study will involve 112 participants who will undergo two 9-month periods of either true HEPA filtration or sham filtration, separated by a 3-month wash-out period. Researchers will monitor indoor air quality and collect health data, including vascular function and blood pressure, to assess the impact of reduced indoor fine particulate matter exposure on heart disease progression.
Who should consider this trial
Good fit: Ideal candidates are adults aged 65 to 84 years with a stable history of ischemic heart disease living in Los Angeles County.
Not a fit: Patients with active cancer treatments or significant neurological diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly slow the progression of heart disease in patients with a history of ischemic heart disease.
How similar studies have performed: While the approach of using air filtration for health benefits is promising, this specific intervention has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 65 and 84 years old; * Weight ≥ 110 pounds; * Nonsmokers for at least 1 year; * Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records; * Both English and Spanish speaking participants will be included in the recruitment; * Live in the Los Angeles County. Exclusion Criteria: * Have history of degenerative disease of the nervous system such as dementia and Alzheimer's; * Currently have active cancer treatments; * The residential house has already had HEPA filters; * Participants will move out from the current residential address in the next 2 years; * Participants will spend more than 1 month living outside the primary home; * Have any health conditions that prohibit collecting health and covariate data and biospecimens; * Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.
Where this trial is running
Los Angeles, California
- Keck School of Medicine, University of Southern California — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Zhanghua Chen, PhD — University of Southern California
- Study coordinator: Zhanghua Chen, PhD
- Email: zhanghuc@usc.edu
- Phone: 323-442-2109
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.